Patients on BTK inhibitors should be continued on the possibility that these agents may reduce rates of COVID-19 pulmonary manifestations.11,12 Cessation of treatment also has a high risk of causing IgM rebound, potentially increasing risk of constitutional symptoms (which can be confused as COVID-19 related) and symptomatic hyperviscosity.13 This evidence concerns the gene CD40LG and COVID-19.